Laboratory indicators of pathological changes in patients with chronic heart failure with metabolic syndrome

A P Roytman1, N A Sedova1,2, M A Godkov1,3

  • 1FGBOU DPO «Russian medical Academy of continuing professional education of the Ministry of health of the Russian Federation».

Insights

Metabolic syndrome (MS) worsens chronic heart failure (CHF) outcomes. Elevated NT-proBNP, ST-2, and CRP markers, when ranked, predict CHF prognosis and mortality risk in patients with MS.

Area of Science:

  • Cardiology
  • Biomarkers
  • Metabolic Syndrome

Background:

  • Metabolic syndrome (MS) is a significant risk factor for cardiovascular diseases, including chronic heart failure (CHF).
  • Understanding the interplay of specific biomarkers in CHF patients with MS is crucial for prognosis.

Purpose of the Study:

  • To investigate the levels and correlations of NT-proBNP, ST-2, and CRP in CHF patients with and without MS.
  • To assess the utility of these markers, when ranked, in predicting CHF outcomes.

Main Methods:

  • Comparative analysis of NT-proBNP, ST-2, and CRP levels in two groups: CHF without MS (n=37) and CHF with MS (n=37).
  • Patient stratification based on a composite rank of biomarker concentrations.
  • Correlation analysis between biomarkers and patient outcomes (mortality, improvement).

Main Results:

  • Patients with CHF and MS showed higher average levels of ST-2 and CRP compared to those without MS.
  • A higher proportion of CHF patients with MS (59%) had elevated biomarker ranks (6-9) versus those without MS (38%).
  • Elevated biomarker ranks (6-9) were strongly associated with mortality (17/18 deaths) and less so with improvement in CHF patients.

Conclusions:

  • The combination and ranking of NT-proBNP, ST-2, and CRP levels offer valuable prognostic information in CHF.
  • These ranked biomarkers can help identify CHF patients at higher risk of adverse outcomes, particularly those with co-existing metabolic syndrome.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
324
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
516
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
79
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.1K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
174
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
207